Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodríguez-Barrios F, d'Arrigo R, Ciccozzi M, Bertoli A, d'Arminio Monforte A, Balzarini J, Antinori A, Perno CF. Ceccherini-Silberstein F, et al. J Virol. 2005 Aug;79(16):10718-29. doi: 10.1128/JVI.79.16.10718-10729.2005. J Virol. 2005. PMID: 16051864 Free PMC article.
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
Svicher V, Aquaro S, D'Arrigo R, Artese A, Dimonte S, Alcaro S, Santoro MM, Di Perri G, Caputo SL, Bellagamba R, Zaccarelli M, Visco-Comandini U, Antinori A, Narciso P, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. J Infect Dis. 2008 May 15;197(10):1408-18. doi: 10.1086/587693. J Infect Dis. 2008. PMID: 18419549
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
Santoro MM, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, Torti C, Di Perri G, Barbarini G, Bini T, Melzi S, Caramello P, Maserati R, Narciso P, Micheli V, Antinori A, Perno CF; CARe Study Group. Santoro MM, et al. Infection. 2009 Jun;37(3):233-43. doi: 10.1007/s15010-008-8065-4. Epub 2009 Jan 23. Infection. 2009. PMID: 19169632
Resistance to novel drug classes.
Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Marcelin AG, et al. Curr Opin HIV AIDS. 2009 Nov;4(6):531-7. doi: 10.1097/COH.0b013e328331d4b1. Curr Opin HIV AIDS. 2009. PMID: 20048722 Review.
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF. Ceccherini-Silberstein F, et al. Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48. doi: 10.1128/AAC.01720-09. Epub 2010 May 17. Antimicrob Agents Chemother. 2010. PMID: 20479206 Free PMC article.
334 results